Richard Branson is pushing beyond the revenue curve with a new iPad magazine he plans to show to the public next week. The British mogul bills it as a as a paperless “revolutionary multimedia” publication. First word of the pro…
We all wonder why Wall Street pros make so much more money than everyone else. But investment bankers are pikers compared to hedge fund managers, who make their money by taking a small cut of the assets they attract as well as a larger slice of the pro…
Here’s a roundup of some of Wednesday’s major pharmaceutical news: An FDA panel gave Human Genome Sciences a boost with a thumbs-up for its lupus drug, Benlysta; Merck’s experimental heart drug appears to work well without side…
Unlike generics, which are the exact chemical copies of a brand-name drug, biosimilars have large and often complex proteins that are made in living cells, and tiny differences can play havoc with the product. It may take years…
At a liver disease conference in Boston, one highlight is expected to be reports from Achillion about its new hepatitis C treatments, especially ACH-1625. The buzz is growing that the little biotech is attracting the attention …